Study of Weekly DCF to Treat Advanced Gastric Cancer

Launched by FUDAN UNIVERSITY · Dec 5, 2007

Keywords

ClinConnect Summary

Recently,in a multi-center, open-label randomized phase III study (V325), compared to the control arm of CF regimen, DCF showed higher efficacy in terms of response rate, time to progression and overall survival. But the regimen had increased grade 3-4 neutropenia (82% vs 57%) and febrile neutropenia infection (29% vs 12%). We began to study on weekly DCF in the patients with advanced gastric cancer to evaluate the efficacy no less than that of 3-week' regimen.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 70 years
• • Patients with histologically confirmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma
• • ECOG performance status ≤1,life expectancy more than 3 months,
• • Normal laboratory findings:absolute neutrophil count and platelet count ≥ 2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL, transaminases ≤ 1.5 times upper normal limit) and renal function (calculated creatinine clearance ≥ 60 ml/min).
• • Measurable disease according to the RECIST.
• Exclusion Criteria:
• • Pregnant or lactating women
• • Serious uncontrolled diseases and intercurrent infection
• • The evidence of CNS metastasis
• • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
• • Received other chemotherapy regimen after metastasis
• • Used taxane in adjuvant settings
• • Participated in other clinical trials.